Replimune Group, Inc.

NASDAQ•REPL

CEO: Mr. Philip Astley-Sparke F.S.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2018-07-20

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Contact Information

500 Unicorn Park Drive, Suite 303, Woburn, MA, 01801, United States

781-222-9600

www.replimune.com

Market Cap

$308.82M

P/E (TTM)

-1.1

22.3

Dividend Yield

52W High

$13.24

52W Low

$1.50

52W Range

19%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 9-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2017-2025

Financial Dashboard

Q3 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.77+0.00%

4-Quarter Trend

FCF

-$66.09M+0.00%

4-Quarter Trend

2026 Q3 Earnings Highlights

Key Highlights

R&D Spending Ramps Up Nine-month R&D expenses reached $168.9M, increasing $33.4M, driven by RP1 confirmatory study costs and RP2 enrollment.

Operating Loss Widens Nine-month net loss totaled $(240.7M)$, significantly wider than prior year's $(173.2M)$ loss due to increased operating costs.

SG&A Prepares Launch SG&A expenses grew $30.9M to $77.7M for nine months, reflecting pre-commercial infrastructure buildout and personnel costs.

Cash Runway Extended Cash runway extends past 12 months, supported by $35.0M debt draw and $20.8M January ATM proceeds.

Risk Factors

Regulatory Approval Uncertainty RP1 BLA resubmission review ongoing with PDUFA date set for April 10, 2026; negative outcome risks viability.

Internal Control Material Weakness Identified material weaknesses in IT general controls; remediation efforts are ongoing but not yet fully effective.

High Cash Burn Rate Net cash used in operating activities increased to $(224.2M)$ for nine months, requiring continued external financing.

Commercialization Hurdles Remain Success depends on market acceptance, reimbursement, and competition, especially if RP1 faces further regulatory limitations.

Outlook

RP1 BLA Review Status Evaluating FDA feedback following BLA resubmission; next steps determined by April 2026 PDUFA decision timeline.

Advancing RP2/RP3 Pipeline Enrolling patients in RP2 REVEAL study expansion and planning preliminary data release for RP2 HCC cohort by end of 2026.

Funding Operations Forecast Current capital, including recent debt/equity raises, expected to fund operations through at least Q1 2027.

Continued High Operating Costs Expect continued substantial expenses and increasing operating losses for at least the next several years due to development.

Peer Comparison

Revenue (TTM)

IOVA

$285.61M

+34.3%

VALN

$197.09M

+3.0%

DNA

$141.31M

-40.5%

Gross Margin (Latest Quarter)

VIR

9793.1%

-54902.1pp

ALT

100.0%

-299200.0pp

ATXS

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
VIR	$1.57B	-3.1	-53.3%	8.4%
IOVA	$1.32B	-4.4	-50.2%	5.1%
MGTX	$916.32M	-7.0	4438.9%	36.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 14, 2026

EPS:-$0.71

Revenue:$948.01K

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data